ADMA Biologics (ADMA) Competitors $19.33 +0.63 (+3.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$19.48 +0.16 (+0.80%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADMA vs. ACAD, AKRO, ALLO, FGEN, GMAB, MRNA, RDY, QGEN, VTRS, and ASNDShould you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Akero Therapeutics (AKRO), Allogene Therapeutics (ALLO), FibroGen (FGEN), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. ADMA Biologics vs. Its Competitors ACADIA Pharmaceuticals Akero Therapeutics Allogene Therapeutics FibroGen Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation. Which has preferable earnings & valuation, ACAD or ADMA? ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$957.80M4.11$226.45M$1.3717.18ADMA Biologics$426.45M10.82$197.67M$0.8522.74 Is ACAD or ADMA more profitable? ADMA Biologics has a net margin of 45.01% compared to ACADIA Pharmaceuticals' net margin of 22.97%. ADMA Biologics' return on equity of 47.16% beat ACADIA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals22.97% 17.46% 10.75% ADMA Biologics 45.01%47.16%30.51% Does the media prefer ACAD or ADMA? In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 10 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.81 beat ACADIA Pharmaceuticals' score of 0.42 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk and volatility, ACAD or ADMA? ACADIA Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Do analysts recommend ACAD or ADMA? ACADIA Pharmaceuticals presently has a consensus target price of $28.13, indicating a potential upside of 19.53%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 43.13%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.71ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do institutionals & insiders believe in ACAD or ADMA? 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryACADIA Pharmaceuticals and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks. Get ADMA Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADMA vs. The Competition Export to ExcelMetricADMA BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.61B$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio22.746.3119.2822.29Price / Sales10.82309.96440.8796.30Price / Cash35.7141.6335.0757.18Price / Book13.068.488.255.54Net Income$197.67M-$55.06M$3.25B$259.88M7 Day Performance7.33%-3.99%-3.73%-4.66%1 Month Performance6.56%9.58%4.28%4.40%1 Year Performance65.36%6.70%25.85%17.92% ADMA Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADMAADMA Biologics4.2795 of 5 stars$19.33+3.4%$27.67+43.1%+57.7%$4.61B$426.45M22.74530Upcoming EarningsACADACADIA Pharmaceuticals3.9856 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.79B$996.28M16.51510News CoverageUpcoming EarningsAnalyst RevisionAKROAkero Therapeutics3.9565 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$3.93BN/A-25.2530Positive NewsUpcoming EarningsALLOAllogene Therapeutics2.9788 of 5 stars$1.47-2.0%$8.44+474.5%-60.6%$321.53M$20K-1.20310News CoverageUpcoming EarningsFGENFibroGen4.4017 of 5 stars$7.21-3.2%$250.00+3,367.4%-41.4%$29.14M$7.00M-2.88570Upcoming EarningsGMABGenmab A/S3.6306 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$14.81B$3.12B13.122,682News CoverageShort Interest ↑MRNAModerna4.4664 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownRDYDr. Reddy's Laboratories2.2908 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.28B$3.81B22.2827,811QGENQiagen3.2115 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.34B$1.98B127.875,765News CoveragePositive NewsUpcoming EarningsVTRSViatris2.2064 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$10.87B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0689 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.04B$368.70M-26.141,017Analyst Forecast Related Companies and Tools Related Companies ACAD Alternatives AKRO Alternatives ALLO Alternatives FGEN Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives QGEN Alternatives VTRS Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADMA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADMA Stock Alerts